Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 2 |
2019 | 3 |
2020 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Accès précoce aux produits de santé en France : des avancées majeures du CSIS (Conseil stratégique des industries de santé) à concrétiser (modalités, réglementations, financements).
Therapie. 2019 Feb;74(1):87-101. doi: 10.1016/j.therap.2018.11.009. Epub 2018 Dec 6.
Therapie. 2019.
PMID: 30612729
French.
No abstract available.
Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France.
Gaugain L, Cawston H, Dubois de Gennes C, Sanchez Alvares J, Nahon P, Mazaleyrat B, Le Dissez C.
Gaugain L, et al. Among authors: mazaleyrat b.
PLoS One. 2023 Jan 18;18(1):e0280442. doi: 10.1371/journal.pone.0280442. eCollection 2023.
PLoS One. 2023.
PMID: 36652428
Free PMC article.
Item in Clipboard
Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France.
Marine S, Stéphane R, Nicolas P, Felizzi F, Paracha N, Benjamin M, Perol M.
Marine S, et al. Among authors: benjamin m.
J Med Econ. 2020 May;23(5):464-473. doi: 10.1080/13696998.2020.1718156. Epub 2020 Feb 13.
J Med Econ. 2020.
PMID: 31951770
Free article.
Item in Clipboard
Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France.
Clay E, Cristeau O, Chafaie R, Pinta A, Mazaleyrat B, Cottin V.
Clay E, et al. Among authors: mazaleyrat b.
J Mark Access Health Policy. 2019 Jun 24;7(1):1626171. doi: 10.1080/20016689.2019.1626171. eCollection 2019.
J Mark Access Health Policy. 2019.
PMID: 31275535
Free PMC article.
Item in Clipboard
Early access to health products in France: Major advances of the French "Conseil stratégique des industries de santé" (CSIS) to be implemented (modalities, regulations, funding).
Albin N, Chassagnol F, Bergmann JF; participants of Giens XXXIV Round Table “Organisational and regulatory aspects”; with collaboration.
Albin N, et al.
Therapie. 2019 Feb;74(1):103-117. doi: 10.1016/j.therap.2018.12.002. Epub 2018 Dec 13.
Therapie. 2019.
PMID: 30745156
Item in Clipboard
Cite
Cite